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Objectives: To assess the economic burden of cancer by estimating years of poten-
tial productive life lost (YPPLL) and costs of lost productivity due to premature can-
cer-related mortality across Europe. MethOds: We derived the number of cancer 
deaths by sex for 23 of the most common cancer sites in 30 European countries from 
GLOBOCAN. YPPLL were calculated by multiplying the number of cancer-specific 
deaths for each productive age group (15-64) by standard life expectancy at the 
mid-point for each age group. Using the human capital approach, we multiplied 
standardised YPPLL for each individual by country- age- and gender-specific annual 
wages from age of death until retirement following adjustments for labour force 
participation and unemployment. Costs were expressed in 2008€ . Results: All 
cancer sites combined generated a total of € 150.9 billion in premature mortality 
costs in Europe in 2008. Western Europe accounted for almost half of the total, 
followed by Northern (21%), Southern (21%) and Central & Eastern Europe (9%). 
Findings contrasted with YPPLL where Central & Eastern Europe had the highest 
burden. Male costs exceeded female costs by 88% in Europe as a whole (male: € 98.4 
billion; female: € 52.5 billion) and across all European regions. Lung was the most 
expensive site (€ 34.7 billion; 23% of total costs), followed by breast cancer (€ 13.6 
billion, 9%), colorectal cancer (€ 12.1 billion, 8%), brain & CNS (€ 9.1 billion, 6%) and 
pancreatic cancer (€ 7.5 billion, 5%). According to premature mortality cost per death, 
testicular cancer was the most expensive site (€ 2.5 million per death), followed by 
brain & CNS cancer (€ 481,512) and Hodgkin lymphoma (€ 474,559). cOnclusiOns: 
Lost productivity costs due to cancer-related premature mortality are significant in 
Europe. Productivity costs provide an alternative perspective on the cancer burden 
on society and may inform cancer control policy decisions.
ConCeptual papers
Cp1
InCremental Cost per QualIty-adjusted lIfe year GaIned? the need 
for alternatIve methods to evaluate medICal InterventIons for 
ultra-rare dIsorders
Schlander M.1, Garattini S.2, Kolominsky-Rabas P.3, Nord E.4, Persson U.5, Postma M.6, 
Richardson J.7, Simoens S.8, Sola Morales O.9, Tolley K.10, Toumi M.11
1University of Heidelberg, Wiesbaden, Germany, 2Mario Negri Institute for Pharmacological 
Research, Milano, Italy, 3University of Erlangen-Nuremberg, Erlangen, Germany, 4Norwegian 
Institute of Public Health, Oslo, Norway, 5The Swedish Institute for Health Economics, Lund, 
Sweden, 6Unit of PharmacoEpidemiology & PharmacoEconomics (PE2), Department of Pharmacy, 
University of Groningen, Groningen, The Netherlands, 7Monash University, Melbourne, Australia, 
8KU Leuven, Leuven, Belgium, 9HITT, Barcelona, Spain, 10Tolley Health Economics, Buxton, UK, 
11University Claude Bernard Lyon 1, Lyon, France
Objectives: To critically appraise the problems posed by the systematic valua-
tion of interventions for ultra-rare disorders using conventional health economic 
analysis methods. MethOds: An international group of clinical and health eco-
nomic experts met in conjunction with the Annual European ISPOR Congress in 
Berlin/Germany, November 2012, to identify and deliberate underlying issues openly, 
adhering to the Chatham House rule. Results: The group reached a broad consen-
sus, including: The complexities of research and development new treatments for 
ultra-rare disorders (URDs) may require conditional approval and reimbursement 
policies, such as coverage with evidence development agreements, but should not 
be used as a justification for showing surrogate endpoint improvement only. As a 
prerequisite for value assessment, demonstration of a minimum significant clinical 
benefit should be expected within a reasonable timeframe. Regarding the economic 
evaluation of interventions for URDs, the currently prevailing logic of cost effective-
ness (using benchmarks for the maximum allowable incremental cost per quality-
adjusted year, QALY, gained) was considered inappropriate since it does not capture 
well-established social preferences regarding health care resource allocation. Such 
social preferences include, but are not limited to, a priority for care for the worse of 
(related to initial health state), for those with more urgent conditions (the so called 
“rule of rescue”), a relatively lower priority based upon capacity to benefit, and a 
dislike against “all or nothing” resource allocation decisions that might deprive 
certain groups of patients from any chance to access effective care. cOnclusiOns: 
Alternative paradigms to establish the “value for money” conferred by interventions 
for URDs should be developed with high priority. Such methods should capture and 
reflect prominent societal value judgments, beyond efficiency as conventionally 
defined by QALY maximization under a budget constraint.
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Decision analytical modelling represents an essential tool for undertaking health 
economic evaluation. Markov models provide a mathematical framework for such 
analyses, particularly in the context of assessing the cost-effectiveness of treat-
ments for chronic diseases where economic outcomes are typically extrapolated 
beyond the duration of clinical trials. However, structural uncertainty is a key chal-
lenge, to methodologists and decision makers alike, that has hitherto attracted 
insufficient attention. Best practice guidelines advocate the testing of structural 
assumptions through alternative modelling approaches or conducting scenario 
analyses. It should be recognised, however, that structural differences in model 
design represent a strength, rather than limitation, of the modelling process and 
in fields such as climate modelling, multi-model comparisons and ensemble pre-
dictions have been used extensively as the basis for more robust policy decisions. 
Methods for combining models represents an emerging field in climate modelling, 
but the simplest approach is to treat all models equally and the mean of all model 
predictions has been shown to improve on the ‘best’ model predictions in numerous 
studies. A weighted multi-model approach may also be developed, but this remains 
an area of ongoing debate. To date, health economists have not fully embraced the 
potential of the multi-model paradigm to reduce structural uncertainty. In this work, 
responsive to change particularly in oncology. Therefore the objective of this study 
was to determine the level of responsiveness of the EQ-5D in oncology. MethOds: 
A systematic review identified relevant articles reviewing responsiveness of the 
EQ-5D in adults (EMBASE, Medline). Effects sizes (ES) were calculated for the studies 
identified where not already reported. A meta-analysis was undertaken of the effect 
sizes: homogeneity of variance was assessed (fixed effects) and random effects 
models applied where there was significant heterogeneity. Responsiveness was also 
compared for improvement/deterioration in health status. Analyses were conducted 
in SPSS v18. Results: Data were available from 12 studies (3 breast, 2 prostate, as 
well as ovarian, lung and renal cancers) each with EQ-5D data at a minimum of 2 
time points leading to a total of 45 entries. The overall unweighted ES was -0.26 
(95%CI: -0.31 to -0.21), however there was significant heterogeneity in terms of effect 
sizes (Q(44) = 427.00, p< 0.001) which was accounted for using the random effects 
model (Q(44) = 39.58, p> 0.05). The overall weighted effect size (ES) was -0.17 (95%CI: 
-0.33 to -0.01). The weighted ES for improvement was 0.08 (95%CI: -0.02 to 0.18), and 
-0.52 (95%CI: -0.64 to -0.41) for deterioration. cOnclusiOns: There is considerable 
heterogeneity in the reported effect size of the EQ-5D. Responsiveness of the EQ-5D 
in oncology trials as measured by effect sizes is modest at best. The instrument 
appears to be more sensitive to deterioration in health status than to improvements. 
Further work will explore the ES of the EQ-5d in comparison with responsiveness 
of disease-specific measures and changes in health status.
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Objectives: The responsibility of caring for cancer patients, often suffering from a 
magnitude of health problems, can result in a considerable burden for their caregiv-
ers, both physically and psychologically. The objective of this study was to assess 
the status and extent of clinical research into the burden of caregiving for cancer 
patients. MethOds: ClinicalTrials.gov was searched for all cancer trials that con-
sidered caregiver burden, using a matrix of search terms such as ‘carer’, ‘burden of 
care’ or ‘caregiver’. The impact of geographical location or cancer type on the pro-
portion of trials assessing caregiver burden, the outcome measures used and the 
proportion of trials including caregiver burden as an outcome over time were inves-
tigated. Results: From a total of 36,184 cancer-focused trials documented world-
wide, 1,596 (4%) assessed caregiver burden. Outcome measures included caregiver 
quality of life (QoL), satisfaction with care and mood states. The impact of caregiver 
burden in cancer trials within different world regions varied, with the highest pro-
portion of trials that considered caregiver burden located in Mexico (23%) and Asia 
(14-22%). Trials for five major cancer types (breast, lung, prostate, colorectal, liver) 
assessed caregiver burden at similar frequency (4-5%). Evaluation of completed tri-
als demonstrated that the proportion of cancer trials considering caregiver burden 
increased from < 1% between 1997-2001 to 7% after 2012. cOnclusiOns: Fewer 
than 5% of all cancer trials documented worldwide have evaluated the impact of 
caregiver burden, although geographical variation does exist. The equal assess-
ment of caregiver burden across cancer types may suggest that no single cancer 
type is considered to have a higher degree of caregiver burden. Interestingly, while 
the number of total cancer trials evaluating caregiver burden documented to date 
is relatively low, the incidence has increased over the last 15 years, suggesting that 
the growing importance of caregiver burden is being recognised.
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Objectives: The recent European Medicines Agency (EMA) approval of crizotinib has 
highlighted the potential for regulatory approval to be gained on the basis of pivotal non-
comparative Phase II data. This research aims to determine the circumstances under 
which the EMA will approve submissions on this basis. MethOds: All publicly available 
European Public Assessment Reports (EPARs) were screened up to June 2013. Submissions 
that were based on pivotal Phase II data were identified and the acceptance decision, 
disease, and level of benefit were extracted. Results: Eight drugs (bevacizumab, bort-
ezomib, crizotinib, dasatinib, everolimus, gefitinib, imatinib, ofatumumab) across ten 
indications been submitted to the EMA on the basis of pivotal non-comparative Phase II 
data. All submissions were for entry indications except imatinib, which was also submit-
ted for two further indications on this basis. All, except crizotinib, were for indications 
with no alternative therapies and all were for onology indications except everolimus 
which was for subependymal giant cell astrocytoma (SEGA). All, except crizotinib, were 
EMA designated orphan medical products for these indications. One submission was 
rejected (bevacizumab), one was restricted (ofatumumab), and eight were approved. 
Top-line supportive Phase III data was only available in two submissions (crizotinib and 
everolimus). Overall response rates (ORRs) were the primary endpoints in all submis-
sions except imantinib and dasatinib in leukaemia indications and everolimus in SEGA. 
Rejected drugs had ORRs of 47% (ofatumumab, rejected subpopulation) and 38% (beva-
cizumab). Approved drugs had ORRs of 60% (crizotinib), 58% (ofatumumab, approved 
subpopulation), 40% (imatinib), and 35% (bortezomib). Despite low ORRs, imatinib was 
used to treat a disease with no licensed therapies (gastrointestinal stromal tumours), 
and bortezomib offered a 10% complete remission rate. cOnclusiOns: Pivotal Phase II 
data can support EMA approval if it demonstrates substantial clinical benefits for small 
patient populations with severe diseases that lack therapeutic alternatives.
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administrative censoring, and data generating models. Combining the findings 
from our review and our simulation study, we made practical recommendations on 
the use of adjustment methods in HTA. Results: Our review demonstrates that 
adjustment methods make important limiting assumptions. Our simulation stud-
ies show that the bias associated with alternative methods is highly associated 
with deviations from their assumptions. Our recommended analysis framework 
aims to help researchers find suitable adjustment methods on a case-by-case 
basis. The characteristics of clinical trials and the treatment switching mechanism 
observed within them, should be considered alongside the key assumptions of the 
adjustment methods. cOnclusiOns: The limitations associated with switching 
adjustment methods mean that different methods are appropriate in different 
scenarios. In some scenarios all methods may be prone to important bias. The data 
requirements of adjustment methods have important implications for people who 
design and analyse trials which allow treatment switching.
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Objectives: Decision makers often rely on health economic models populated 
with clinical trial data to inform initial assessments about treatment selection, 
coverage, and reimbursement. To date, there have been few (if any) published model 
re-analyses using real-world evidence (RWE). The purpose of this study is to 1) assess 
real-world health and economic outcomes associated with oral anticoagulant vs. 
low molecular weight heparin (LMWH) as prophylaxis for venous thromboembo-
lism (VTE) in patients undergoing total hip (THR) or knee (TKR) replacement, and 2) 
compare results of a health economic model populated with clinical trial data vs. 
RWE. MethOds: Patients who underwent THR or TKR between July 2011 and June 
2012 were identified in a US commercial insurance claims database. Patients were 
required to be continuously enrolled 3 months pre-/post-index and were excluded if 
treated with multiple anti-coagulants within 10 days post-index. A propensity score 
matching technique was employed to reduce selection bias. Patient characteristics, 
inpatient-related VTE events and health care costs were determined. A health eco-
nomic model previously parameterized with clinical trial data was repopulated and 
reanalyzed using inputs derived from the claims study. Results: A total of 14,880 
patients were identified (7,440 oral anticoagulant, 7,440 LMWH). In both groups, 
mean age was 59 and 53% were female. Compared with LMWH, oral anticoagulant 
use was associated with fewer symptomatic VTE events over 1-year. When repopu-
lated with clinical inputs from claims data, the model projected similar VTE event 
differences as trial-based model (-0.023 vs. -0.015). Costs (per patient/year) in oral 
anticoagulant and LMWH groups were consistent across the trial-based model ($385 
vs. $1,011), claims-based model ($437 vs. $1,290), and direct reported results from 
claims analysis ($506 vs. $1,125). cOnclusiOns: Use of RWE is a practical and 
objective way to validate a trial-based health economic model. Future work should 
consider study design issues and practical use of results.
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Objectives: We developed an individual-based micro-simulation model for radio-
therapy treatment in non small-cell lung cancer (NSCLC). The aim was to explore 
the suitability of multi-state statistical modelling in heath economics, as a tool to 
parameterize a simulation model that tracks clinical events over time, taking patient 
and tumour features into account. MethOds: The model contains the four clinical 
states ‘A: alive without local recurrence (LR) or metastasis (M)’, ‘LR’, ‘M’, and ‘Death’. 
Transition rates were estimated using multi-state statistical modelling, a technique 
that allows the simultaneous estimation of hazards for multiple transitions, taking 
covariates as well as the occurrence and timing of previous events into account. Each 
of the hazards from A to either LR, M and Death were adjusted for the presence of the 
other competing risks. Individual patients were simulated by repeatedly sampling 
a patient profile, consisting of patient and tumour characteristics. Subsequently, for 
each patient a pathway through the model was simulated. The internal validity of 
the model was verified by comparing intermediate simulation outcomes and overall 
survival under two different radiotherapy strategies to the original data used for 
estimation. Finally, the model was externally validated by comparing model outcomes 
to Dutch cancer registry data. Results: Model simulations for the two radiotherapy 
strategies demonstrated internal validity, with predicted probabilities for the occur-
rence of LRs, Ms, deaths, and the occurrence of toxicities within 3 years that fell within 
the 95% confidence intervals of the data. The same was observed for the prediction 
of overall survival. Comparison of the model predictions to the Dutch cancer registry 
data showed a moderate fit. cOnclusiOns: Multi-state statistical modelling is a 
useful technique for obtaining the transition rates that are required for the quantifi-
cation of a micro-simulation model. In future, our model will be used to evaluate the 
cost-effectiveness of individualized treatment strategies.
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we illustrate how this approach may be developed to a) simultaneously and system-
atically compare health economic outcomes predicted by multiple Markov models; 
b) address the question of whether (and how) to weight different models within an 
ensemble based on different performance metrics and model skill scores; c) identify, 
quantify, and partition total uncertainty across a multi-model ensemble into different 
sources (for example, to highlight where future research priorities may optimally lie to 
further improve the robustness of policy recommendations through model improve-
ment and data collection); and d) apply this approach to some real-world examples.
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Objectives: Qualitative interviews, as tools for scientific evidence generation, are 
often excluded from consideration in health outcomes research. Lack of methodologi-
cal rigour and the non-reproducibility and non-generalizability of results are often 
used to justify quantitative methodologies. Here we present an illustrative exam-
ple of qualitative interviewing’s value within health outcomes research. In a study 
aiming to measure patient and physician preferences for hepatitis C treatments, a 
discrete choice experiment was designed and a systematic literature review was 
conducted. MethOds: To assess the comprehensibility and relevance of the ques-
tionnaire as well as to estimate the value and preciseness of assumptions, pre-tests 
consisting of a questionnaire pilot followed by a semi-direct interview were con-
ducted. The semi-direct interviewing followed rigorous methods, including defined 
themes assembled in a discussion guide and behavioural rules for the interviewer 
to promote axiological neutrality. Analytical methods using predefined codes for 
the interpretation enabled a systematic understanding of datasets. Results: The 
qualitative component mostly validated but sometimes challenged the theoretical 
assumptions of the discrete-choice experiment, which had been previously developed 
on the basis of the systematic literature review. Interviews shed light on occasional 
complexity and lack of comprehensibility of some questions. The qualitative analysis 
provided insights to patients’ and physicians’ experience of their treatment selection 
process. It included socio-psychological dispositions, like the aversion for work absen-
teeism or the importance of social representation encouraging patients to prefer treat-
ments which side effects would not affect their social capacities. cOnclusiOns: This 
method provided in-depth and structured feedback from a small group of patients and 
physicians. As health outcomes studies increasingly require to expand their level of 
detail and sensitivity by entering subjective fields of personal preferences, patients’ 
experiences and decision-making processes, there is a pressing need for conduct-
ing qualitative micro-level studies prior to supporting broader, field-based studies.
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Patient preference-based health-related quality of life measures (utilities) are a criti-
cal input in cost-effectiveness analyses of pharmaceuticals and other health care 
technologies. Over recent years it has become more common for utility data to be 
collected alongside key clinical data within the pivotal Phase III trials. However, utility 
data are often not available for all patients throughout the entire course of the trial. 
The authors discuss the concept that there are unique characteristics of utility data 
that need to be considered when dealing with missing values, including the large 
inter-patient variability typically present at baseline. Missing data arise because i) 
patients become more ill and are less able to complete patient-reported instruments, 
ii) patients die during the course of the trial, or iii) patients are censored at later stages 
of the trial due to rolling recruitment. Whilst this is often a problem in oncology trials, 
it is also a consideration in other interventional and observational research designed 
to inform pharmacoeconomic evaluations. Situations where individual patient data 
are accessible and where only summary statistics are available are discussed. The 
practical considerations of how such re-analysed data should then be included within 
an economic model are discussed, given the manner in which utilities are incorpo-
rated will vary depending on the nature of the health states used.
researCh on methods – modelInG studIes
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Objectives: Treatment switching is a common issue in clinical trials of cancer 
treatments – often patients randomised to the control group are permitted to 
switch onto the experimental treatment at some point during follow-up. In such 
circumstances an intention to treat (ITT) analysis will result in biased estimates 
of the overall survival advantage – and therefore the cost-effectiveness – associ-
ated with the experimental treatment. Methods to adjust for switching have been 
used inconsistently and potentially inappropriately in health technology assess-
ments (HTA). We present an analytical framework to guide analysts on the use 
of methods to adjust for treatment switching in the context of economic evalua-
tions. MethOds: We conducted a review of methods used to adjust for treatment 
switching in HTA, and two rigorous simulation studies to assess the performance 
of adjustment methods in a range of realistic scenarios. We tested different simu-
lated trial sample sizes, crossover proportions, treatment effect sizes, levels of 
